Thomas Steyer’s Krystal Biotech KRYS Stock Holding History

Thomas Steyer’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,000	Closed	-$258K	–	140
2026 Q1	$258K	Sell	1,000 -1,000	-50%	-$266K	﹤0.01%	128
2025 Q4	$493K	Hold	2,000	–	–	﹤0.01%	95
2025 Q3	$353K	Hold	2,000	–	–	﹤0.01%	98
2025 Q2	$275K	Hold	2,000	–	–	﹤0.01%	106
2025 Q1	$361K	Hold	2,000	–	–	﹤0.01%	101
2024 Q4	$313K	Hold	2,000	–	–	﹤0.01%	109
2024 Q3	$364K	Hold	2,000	–	–	﹤0.01%	114
2024 Q2	$367K	Hold	2,000	–	–	﹤0.01%	114
2024 Q1	$356K	Hold	2,000	–	–	﹤0.01%	128
2023 Q4	$248K	Hold	2,000	–	–	﹤0.01%	119
2023 Q3	$232K	Buy	+2,000	New	+$244K	﹤0.01%	125
2021 Q3	–	Sell	-75,000	Closed	-$5.1M	–	306
2021 Q2	$5.1M	Sell	75,000 -550,000	-88%	-$38.4M	0.02%	174
2021 Q1	$48.1M	Buy	625,000 +100,000	+19%	+$7.27M	0.24%	72
2020 Q4	$31.5M	Buy	525,000 +50,000	+11%	+$2.5M	0.19%	78
2020 Q3	$20.4M	Buy	475,000 +25,000	+6%	+$1.09M	0.14%	84
2020 Q2	$18.6M	Buy	450,000 +200,000	+80%	+$9.62M	0.15%	91
2020 Q1	$10.8M	Buy	+250,000	New	+$13.1M	0.09%	78

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Thomas Steyer's KRYS Position: Q2 2026 in Review

Thomas Steyer sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1,000 shares — an estimated $258K sold.

Thomas Steyer first reported a position in KRYS in Q1 2020 and held it in 17 quarters. The position peaked at $48.1M in Q1 2021. 420 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Thomas Steyer reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
Thomas Steyer sold 1,000 Krystal Biotech shares in Q2 2026, an estimated $258K.
Thomas Steyer first reported a position in Krystal Biotech in Q1 2020 and held it in 17 quarters.
Thomas Steyer's Krystal Biotech position peaked at $48.1M in Q1 2021.
420 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.